Current balloon expandable transcatheter valves have limited applicability to patients with "native" right ventricular outflow tracts (RVOT), meaning those who have had previous surgery and are left with large, compliant, irregular RVOT. The Alterra Adaptive Prestent TM is a self-expanding, partially covered stent that was designed to internally reconfigure these types of RVOT, making them suitable for implantation of a commercially available balloon expandable heart valve, the SAPIEN 3.
monary regurgitation requiring pulmonary valve placement. With time and degeneration of surgically implanted valves, multiple open-heart surgeries are often required. While transcatheter pulmonary valve placement was first described nearly 2 decades ago by Bonhoeffer et al. [1] , current balloon expandable valves are better suited to the size and geometry of surgical conduits and bioprosthetic valves [2] . The "native" RVOT, usually characterized by a variable and dynamic morphology, large diameter, and unpredictable compliance often precludes transcatheter valve replacement with existing devices [3] . The Alterra Adaptive Prestent TM was designed to internally remodel a wide variety of RVOT morphologies, thereby creating a suitable "landing zone" for implantation of a standard balloon expandable transcatheter heart valve (THV) in an attempt to treat a broader range of patients. Herein, we describe the first successful human implant of this device.
| D EV I CE DE SCR I P TI ON
The Alterra Adaptive Prestent is designed to be used as a docking adaptor for the 29 mm SAPIEN 3 THV within the RVOT. It is comprised of a self-expanding, radiopaque, nitinol frame assembly and polyethylene terephthalate (PET) fabric covering and has designated inflow and outflow ends ( Figure 1 
| Delivery system description
The Alterra Adaptive Prestent comes fully loaded in a custom delivery system consisting of a handle, retractable outer shaft, inner delivery shaft (upon which the stent sits), prestent connector, and a tapered tip 
| CA S E RE P O RT
A 48-year-old woman who was born with an initial diagnosis of valve and sub-valve pulmonic stenosis underwent operative repair as a child (1978) RVOT (e.g., transannular patch, surgical valvotomy, etc.) commonly develop significant pulmonary regurgitation. As the long-term outcomes of these patients become more clearly defined, it appears that the majority will ultimately benefit from placement of a competent, non-obstructive pulmonary valve [6] . While surgical valve placement remains a viable option, it comes with all of the attendant risks, morbidities, and discomfort associated with repeat open-heart surgical procedures [7] . Currently available balloon expandable THVs have been successfully placed in selected patients with "native" RVOT, however, the vast majority are not suitable anatomic candidates due to the large size and compliant nature of their RVOT [8, 9] .
Several centers have recently reported unique approaches to reconfiguring the RVOT in this patient population so as to make them candidates for transcatheter pulmonary valve therapy [10, 11] . Our group recently published our experience with a hybrid approach designed to remodel the RVOT using an intravascular technique [10] .
In that study, a subxiphoid approach was used to simultaneously place a "landing-zone" stent alongside 1-3 covered stents filled with vascular plugs in an effort to reduce the volume of the RVOT, thereby allowing for implantation of a balloon expandable transcatheter valve. Other centers have used off-pump surgical approaches to plicate or band the RVOT in an effort to create a "landing zone" for a balloon expandable valve [11] . The Alterra Adaptive Prestent was designed to facilitate internal RVOT remodeling providing a predictable rigid "landing zone"
for a balloon expandable valve through a simple catheter-based approach. The concept of preparing the RVOT for a transcatheter valve implant with a prestent is well ingrained in the congenital interventional community and has been shown to have numerous benefits including:
providing a stable and safe "landing zone" for valve placement, protection of valve components from extrinsic forces which could lead to valve dysfunction and longer freedom from re-intervention [12] . In the case presented, the ability of this new device to successfully reduce the effective diameter of a large "native RVOT" and create a suitable As described by others [13] , the tremendous variability of RVOT anatomy in this population makes pre-procedural cross-sectional imaging a vital tool in selecting patients and procedural planning. Furthermore, the ability to create systolic and diastolic three-dimensional models in which to perform pre-procedural virtual "implants" was felt to have added greatly to the success of this initial implant and will likely be of value going forward, particularly early in one's learning curve.
| C ONC LUSI ON
The patient described in this report was implanted as part of an early feasibility study in the United States. While this initial report is encouraging, much more remains to be evaluated about this novel approach to this complex group of patients.
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